Baiju Shah, JD
Investment & Commercial Development Advisor
Baiju R. Shah is the Managing Director of Accelevate Ventures, an advisory firm focused on catalyzing and accelerating innovation to impact. Through the firm, he supports the launch and growth, of companies, innovation platforms, and investment funds. Mr. Shah also serves as the Senior Fellow for Innovation at The Cleveland Foundation and a Senior Advisor to FasterCures, a center of the Milken Institute.
Baiju previously served as Chief Executive Officer and Board Member of BioMotiv, and co-leader of The Harrington Project for Discovery & Development, a $360 million US and UK drug development initiative, both of which he co-founded in 2012 and led through early 2019. During Mr. Shah’s tenure, BioMotiv established strategic partnerships with Takeda, Biogen, Arix Bioscience, and Charles River Laboratories, and partnered programs with Bristol-Myers Squibb, AstraZeneca, and Johnson & Johnson.
Prior to BioMotiv, Baiju was President, CEO,
Board Member, and a co-founder of BioEnterprise, a business formation, recruitment and acceleration initiative that directly assists client companies in securing resources and funding to support their growth, and also serves as a catalyst for major industry initiatives such as new capital sources, translational centers, and real estate projects. During Mr. Shah’s tenure, the initiative assisted more than 110 bioscience companies that collectively attracted $1.3 Billion in new funding.
Baiju is a Board Director of Invacare (NYSE: IVC) and serves on the Impact Investments Board for The Cleveland Foundation. He began his business career as a consultant with McKinsey & Company. He has been named an Ernst & Young Entrepreneur of the Year and has been recognized as one of Cleveland’s most influential leaders. He received a J.D. from Harvard Law School and a B.A. from Yale University.
Lynne has lead numerous successful regulatory filings and agency interactions (Pre-IND, INDs, NDA/BLAs, scientific advice, EOP2, and Pre-NDA) in the US and Europe and had written and/or contributed to over 30 pediatric study plans.